BUZZ- Plus Therapeutics rises as it secures new billing code for cancer test
Reuters04-07
BUZZ- Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises as it secures new billing code for cancer test
** Shares of biotech firm Plus Therapeutics PSTV.O rise 3.6% to $3.45 premarket
** Co says the American Medical Association approved a new billing code for its CNSide test, effective July 1, 2026
** CNSide is used to detect cancer cells in spinal fluid in patients whose cancer has spread to the brain and spinal cord, a serious and often hard‑to‑diagnose condition - PSTV
** Says the new code should make it easier for doctors and hospitals to bill insurers, supporting wider use of the test
** Co says the approval marks a key step in the U.S. commercial rollout of its diagnostics business
** As of last close, stock down ~21% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments